04 September 2020 : Clinical Research
Clinical Characteristics and Outcomes of Patients with Severe COVID-19 and Chronic Obstructive Pulmonary Disease (COPD)
Yuanzhou He1BCG, Min Xie1DE, Jianping Zhao1CF, Xiansheng Liu1A*DOI: 10.12659/MSM.927212
Med Sci Monit 2020; 26:e927212
Table 3 Baseline characteristics of survivors and non-survivors with severe COVID-19 patients.
| Total (n=336) | Survivors (n=203) | Non-survivors (n=133) | P value | |
|---|---|---|---|---|
| Number (%) | Number (%) | Number (%) | ||
| * | 65 (50–77) | 48 (36–69) | 69 (57–80) | |
| Male | 201 (59.8) | 100 (49.3) | 101 (75.9) | |
| Female | 135 (40.2) | 103 (50.7) | 32 (24.1) | |
| COPD | 28 (8.3) | 6 (3.0) | 22 (16.5) | |
| Essential hypertension | 128 (38.1) | 67 (33.0) | 61 (45.9) | |
| Diabetes | 78 (23.2) | 35 (17.2) | 43 (32.3) | |
| Cardiovascular disease | 59 (17.6) | 23 (11.3) | 36 (27.1) | |
| Cerebrovascular disease | 15 (4.5) | 7 (3.4) | 8 (6.0) | 0.265 |
| Chronic kidney disease | 8 (2.4) | 5 (2.5) | 3 (2.3) | 0.903 |
| Chronic liver disease | 3 (0.9) | 2 (1.0) | 1 (0.8) | 0.824 |
| Malignancy | 14 (4.1) | 8 (3.9) | 6 (4.5) | 0.798 |
| Autoimmune disease | 4 (1.2) | 3 (1.5) | 1 (0.8) | 0.549 |
| 1.98±1.06 | 1.02±0.93 | 2.46±1.23 | ||
| 158 (47.0) | 53 (26.1) | 105 (78.9) | ||
| 196 (58.3) | 75 (37.0) | 121 (91.0) | ||
| ** | 136 (40.5) | 13 (6.4) | 123 (92.5) | |
| *** | 14 (8–19) | 16 (12–24) | 10 (5–14) | |
| * Data reported as IQR, years; ** invasive mechanical ventilation only; *** data reported as IQR, days. ICU – Intensive Care Unit; SOFA score – Sepsis-related Organ Failure Assessment score. | ||||